2183.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 11:45):

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide...

Stats
आज की मात्रा	31 300.00
औसत मात्रा	104 916
बाजार मूल्य	9.24B
EPS	¥0 ( 2024-02-13 )
अगली कमाई की तारीख	( ¥0 ) 2024-05-12
Last Dividend	¥14.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.41
ATR14	¥1.087 (0.27%)

Linical Co., Ltd. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Linical Co., Ltd. वित्तीय

Annual	2022
राजस्व:	¥12.52B
सकल लाभ:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
राजस्व:	¥12.52B
सकल लाभ:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
राजस्व:	¥11.56B
सकल लाभ:	¥3.61B (31.26 %)
EPS:	¥35.00

FY	2021
राजस्व:	¥10.28B
सकल लाभ:	¥2.77B (26.92 %)
EPS:	¥23.91

Financial Reports:

No articles found.

Linical Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥14.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Linical Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.06 - Decrease likely (38.78%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2009-03-26
Last Dividend	¥14.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	¥111.75	--
Avg. Dividend % Per Year	0.00%	--
Score	2.77	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.06
Div. Directional Score	7.05	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.77

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8387.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7806.T	Ex Dividend Junior	2023-09-28	Sporadic	0.00%
6958.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6310.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
5101.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4238.T	Ex Dividend Knight	2023-07-28	Semi-Annually	0.00%
3454.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
2594.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
9010.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
8113.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0543	1.500	8.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0385	1.200	8.72	10.00	[0 - 0.3]
returnOnEquityTTM	0.0876	1.500	-0.138	-0.206	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.712	0.800	6.44	5.15	[1 - 3]
quickRatioTTM	1.467	0.800	6.08	4.86	[0.8 - 2.5]
cashRatioTTM	1.018	1.500	5.46	8.19	[0.2 - 2]
debtRatioTTM	0.154	-1.500	7.43	-10.00	[0 - 0.6]
interestCoverageTTM	71.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.349	-1.500	8.60	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.324	1.000	7.93	7.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0925	1.000	-0.151	-0.151	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.05	9.05	[0.2 - 2]
assetTurnoverTTM	0.708	0.800	8.61	6.89	[0.5 - 2]
Total Score				11.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.58	1.000	8.73	0	[1 - 100]
returnOnEquityTTM	0.0876	2.50	-0.0884	-0.206	[0.1 - 1.5]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.67	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.242	1.500	-4.95	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0810	1.000	-0.474	0	[0.1 - 0.5]
Total Score				3.06

Linical Co., Ltd.

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.